Fortress Biotech, Inc.
FBIO
Rank in Stocks
#21533
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the... Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.
Share Price
$1.99
Last synced: 2026-11-09
Market Cap
$66.37M
Change (1 day)
7.57%
Change (1 year)
-25.75%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Fortress Biotech, Inc. (FBIO)
Category
Healthcare
Operating Margin for Fortress Biotech, Inc. (FBIO)
Operating Margin as of November 2026 TTM: -42.86%
According to Fortress Biotech, Inc.'s latest financial reports, its current operating margin (TTM) is -42.86%. At the end of 2025 the company had an operating margin of -111.00%.
Operating Margin history for Fortress Biotech, Inc. from 2008 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -42.86% | -61.39% |
| 2025 | -111.00% | -42.00% |
| 2024 | -191.38% | 13.63% |
| 2023 | -168.43% | -37.33% |
| 2022 | -268.76% | -1.94% |
| 2021 | -274.08% | 32.57% |
| 2020 | -206.74% | -31.67% |
| 2019 | -302.54% | -32.22% |
| 2018 | -446.38% | 832.48% |
| 2017 | -47.87% | -87.99% |
| 2016 | -398.73% | -93.19% |
| 2015 | -5,855.27% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.90% |
US
|
|
| -149.01% | -96.52% |
US
|
|
| 25.57% | -100.60% |
AU
|
|
| 31.23% | -100.73% |
BE
|
|
| 29.35% | -100.68% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Fortress Biotech, Inc.'s operating margin
What is Fortress Biotech, Inc.'s operating margin?
Fortress Biotech, Inc.'s operating margin is -42.86%, as of Nov 2026.
What was Fortress Biotech, Inc.'s operating margin in 2025?
In 2025, Fortress Biotech, Inc.'s operating margin was -111.00%, compared with -191.38% in 2024.
How has Fortress Biotech, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Fortress Biotech, Inc.'s operating margin was highest in 2025 (-111.00%) and lowest in 2021 (-274.08%).
How does Fortress Biotech, Inc.'s operating margin compare with similar companies?
Fortress Biotech, Inc.'s operating margin (-42.86%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.